Ex-4.11






Exhibit 4.11




WRIGHT MEDICAL GROUP, INC.

Restricted Stock Grant Agreement

Sales Representative




	 	 	 	 	 
	Award Granted to (“Grantee”):	 	Grant Date:	 	Number of Shares (“Shares”):
	«Name»
	 	«Date of Grant»
	 	«Shares»






          THIS RESTRICTED STOCK GRANT AGREEMENT (the “Agreement”) is made as of the Grant Date by and
between Wright Medical Group, Inc., a Delaware corporation with its principal place of business at
5677 Airline Road, Arlington, Tennessee 38002 (the “Company”) and Grantee pursuant to the Wright
Medical Group, Inc. 1999 Equity Incentive Plan, as amended from time to time (the “Plan”) and which
is hereby incorporated by reference.




          WHEREAS, Grantee is associated with the Company or its affiliate as sales representative; and




          WHEREAS, the Compensation Committee of the Company’s Board of Directors (the “Committee”) has
authorized that Grantee be granted shares of the Company’s Common Stock (“Stock”) subject to the
restrictions stated below;




          NOW, THEREFORE, the parties agree as follows:





	1.	 	Grant of Stock. Subject to the terms and conditions of this Agreement and of the Plan, the
Company hereby grants to Grantee the Shares.
	 
	2.	 	Vesting Schedule. The interest of Grantee in the Shares shall vest as to one-fourth (1/4) of
the Shares on the first anniversary of the Grant Date, and as to an additional one-fourth (1/4)
on each succeeding anniversary date, so as to be 100% vested on the fourth anniversary
thereof, conditioned upon Grantee’s continued association with the Company as of each vesting
date. Notwithstanding the foregoing, the interest of Grantee in the Shares shall vest as to:






	 	2.1.	 	100% of the then unvested Shares upon a Change of Control. For purposes of this
Agreement a “Change of Control” shall mean the first to occur on or after the Grant Date of
any of the following:






(a) The acquisition by any individual, entity or group (within the meaning of Section
13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act) of 50% or more (on a fully diluted basis) of either
(A) the then outstanding shares of Stock, taking into account as outstanding for this
purpose such Stock issuable upon the exercise of options or warrants, the conversion of
convertible stock or debt, and the exercise of any similar right to acquire such Stock
(the “Outstanding Company Common Stock”) or (B) the combined voting power of the then
outstanding voting securities of the Company entitled to vote generally in the election
of directors (the “Outstanding Company Voting Securities”); provided, however, that for
purposes of this subsection (a), the following acquisitions shall not constitute a
Change of Control: (x) any acquisition by the Company or any “affiliate” of the
Company, within the meaning of 17 C.F.R. § 230.405 (an “Affiliate”), (y) any acquisition
by any employee benefit plan (or related trust) sponsored or maintained by the Company
or any Affiliate, (z) any acquisition by any corporation or business entity pursuant to
a transaction which complies with clauses (A) and (B) of subsection (a) of this Section
2.1 (persons and entities described in clauses (x), (y), and (z) being referred to
herein as “Permitted Holders”);




(b) The consummation of a reorganization, merger or consolidation or sale or other
disposition of all or substantially all of the assets of the Company (a “Business
Combination”),



 









 






Restricted Stock Grant Agreement

Page 2




in each case, unless, following such Business Combination, (A) all or substantially all
of the individuals and entities who were the beneficial owners, respectively, of the
Outstanding Company Common Stock and Outstanding Company Voting Securities immediately
prior to such Business Combination beneficially own, directly or indirectly, more than
60% of, respectively, the then outstanding shares of common stock and the combined
voting power of the then outstanding voting securities entitled to vote generally in the
election of directors, as the case may be, of the corporation resulting from such
Business Combination (including, without limitation, a corporation which as a result of
such transaction owns the Company or all or substantially all of the Company’s assets
either directly or through one or more subsidiaries) in substantially the same
proportions as their ownership, immediately prior to such Business Combination, of the
Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case
may be, (B) no Person (excluding any Permitted Holder) beneficially owns, directly or
indirectly, 50% or more (on a fully diluted basis) of, respectively, the then
outstanding shares of common stock of the corporation resulting from such Business
Combination, taking into account as outstanding for this purpose such common stock
issuable upon the exercise of options or warrants, the conversion of convertible stock
or debt, and the exercise of any similar right to acquire such common stock, or the
combined voting power of the then outstanding voting securities of such corporation
except to the extent that such ownership existed prior to the Business Combination, and
(C) at least a majority of the members of the board of directors of the corporation
resulting from such Business Combination were members of the incumbent Board at the time
of the execution of the initial agreement providing for such Business Combination;




(c) The approval by the stockholders of the Company of a complete liquidation or
dissolution of the Company;




(d) The sale of at least 80% of the assets of the Company to an unrelated party, or
completion of a transaction having a similar effect; or




(e) The individuals who on the date of this Agreement constitute the Board of Directors
thereafter cease to constitute at least a majority thereof; provided that any person
becoming a member of the Board of Directors subsequent to the date of this Agreement and
whose election or nomination was approved by a vote of at least two-thirds of the
directors who then comprised the Board of Directors immediately prior to such vote shall
be considered a member of the Board of Directors on the date of this Agreement.




	 	2.2.	 	100% of the unvested Shares upon Grantee’s death.






	3.	 	Restrictions.






	 	3.1.	 	The Shares granted hereunder may not be sold, pledged or otherwise transferred until
the Shares become vested in accordance with this Agreement. The period of time between the
Grant Date and the date the Shares become vested is referred to as the “Restriction
Period.”
	 
	 	3.2.	 	If Grantee’s association with the Company is terminated, the balance of the Shares
subject to the provisions of this Agreement which have not vested at the time of Grantee’s
termination shall be forfeited by Grantee, and ownership transferred back to the Company.
	 
	 	3.3.	 	By accepting the Shares, Grantee represents and agrees for Grantee and Grantee’s
transferees (whether by will or the laws of descent and distribution) that:






(a) For the period commencing on the Grant Date and ending on the first anniversary of
the termination of Grantee’s service (such period is hereinafter referred to as the
“Covenant Period “), with respect to any geographic territories in which the Company is
engaged in business during the period for which Grantee provided service to the Company,
Grantee shall



 









 





 Restricted Stock Grant Agreement

Page 3





not participate or engage, directly or indirectly, for Grantee or on behalf of or in
conjunction with any person, partnership, corporation or other entity, whether as an
employee, agent, officer, director, stockholder, partner, joint venturer, investor or
otherwise, (other than a limited partner or stockholder of less than one percent of the
issued and outstanding limited partnership interests or stock of a publicly held
partnership or corporation whose gross assets exceed $1,000,000) in the distribution,
solicitation, promotion, manufacture, design, development, or sale of any medical
products or services competitive with products manufactured, marketed, or sold by the
Company or any of its subsidiaries or any medical products or services intended to be
manufactured, marketed, or sold by the Company of the same general type or function.




(b) Except with the Company’s prior written approval or as may otherwise be required by
law or legal process, Grantee shall not disclose any material or information which is
confidential to the Company or its subsidiaries and not in the public domain or
generally known in the industry, whether tangible or intangible, made available,
disclosed or otherwise known to Grantee as a result of Grantee’s service with the
Company.




(c) During the Covenant Period, Grantee shall not attempt to influence, persuade or
induce, or assist any other person in so persuading or inducing, any employee of the
Company or its subsidiaries to give up, or to not commence, employment or a business
relationship with the Company.




	 	3.4.	 	The Company shall have the right, but not the obligation, to purchase and acquire from
Grantee any or all of the Shares (the “Repurchased Shares”) if the Committee reasonably
determines that Grantee has violated the covenants set forth in this Agreement or Grantee’s
service is terminated or could have been terminated for Cause (as defined in the Plan).
The Company may exercise the right granted to it under this Section 3.4 by delivering
written notice to Grantee stating that the Company is exercising the repurchase right
granted to it under this Section 3.4. The delivery of such notice by the Company to
Grantee shall constitute a binding commitment of the Company to purchase and acquire all of
the Repurchased Shares. The total purchase price for the Repurchased Shares shall be
delivered to the Participant against delivery by Grantee of certificates evidencing the
Repurchased Shares no later than 30 days after the delivery of the election notice by the
Company. The price per share of the Repurchased Shares shall be the lesser of 1) the Fair
Market Value (as defined in the Plan) of each of the Repurchased Shares on the date of the
Company’s delivery of its written notice to Grantee or 2) the Fair Market Value of each of
the Repurchased Shares on the date that such shares vested to the Grantee without regard to
any election by the Grantee under Section 83(b) of the Internal Revenue Code of 1986, as
amended.
	 
	 	3.5.	 	The Company shall have the right, but not the obligation, to cancel any or all of the
Shares if the Committee reasonably determines that Grantee has violated the covenants set
forth in this Agreement. The Company may exercise the right granted to it under this
Section 3.5 by delivering a written notice to Grantee stating that the Company is
exercising the cancellation right granted to it under this Section 3.5.
	 
	 	3.6.	 	Notwithstanding anything in this Section 3 to the contrary, the Company shall not be
obligated to purchase any Stock at any time to the extent that the purchase would result in
a violation of any law, statute, rule, regulation, order, writ, injunction, decree or
judgment promulgated or entered by any Federal, state, local or foreign court or
governmental authority applicable to the Company or any of its property.
	 
	 	3.7.	 	The parties intend the restrictions in Section 3.3 to be completely severable and
independent, and any invalidity or unenforceabitliy of any one or more such restrictions
shall not render invalid or unenforceable any one or more restrictions.




 









 





Restricted Stock Grant Agreement

Page 4




	4.	 	Legend. All certificates representing any shares of Stock subject to the provisions of this
Agreement shall have endorsed thereon the following legend:






THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO A
RESTRICTED STOCK GRANT AGREEMENT BETWEEN THE
COMPANY AND THE
REGISTERED HOLDER, A COPY OF WHICH IS
ON FILE AT THE PRINCIPAL
OFFICE OF THIS COMPANY.




	5.	 	Escrow. The certificate or certificates evidencing the Shares subject hereto shall be
delivered to and deposited with the Secretary of the Company as Escrow Agent in this
transaction. The Shares may also be held in a restricted book entry account in the name of
Grantee. Such certificates or such book entry shares are to be held by the Escrow Agent until
termination of the Restriction Period, when they shall be released by the Escrow Agent to
Grantee.
	 
	6.	 	Stockholder Rights. During the Restriction Period, Grantee shall have all the rights of a
stockholder with respect to the Shares except for the right to transfer the Shares as set
forth in Section 3 and except as set forth in Section 7. Accordingly, Grantee shall have the
right to vote the Shares and to receive any cash dividends paid to or made with respect to the
Shares.
	 
	7.	 	Changes in Stock. In the event that as a result of (i) any stock dividend, stock split or
other change in the Stock, or (ii) any merger or sale of all or substantially all of the
assets or other acquisition of the Company, and by virtue of any such change Grantee shall in
Grantee’s capacity as owner of unvested shares of Stock which have been awarded to Grantee
(the “Prior Stock”) be entitled to new or additional or different shares or securities, such
new or additional or different shares or securities shall thereupon be considered unvested
Shares and shall be subject to all of the conditions and restrictions which were applicable to
the Prior Stock pursuant to this Agreement.
	 
	8.	 	Permanent and Total Disability of Grantee. In the event of the permanent and total
disability of Grantee, any unpaid but vested Shares shall be paid to Grantee if legally
competent or to a legally designated guardian or representative if Grantee is legally
incompetent.
	 
	9.	 	Death of Grantee. In the event of Grantee’s death after the vesting date but prior to the
payment of the Shares, such Shares shall be paid to Grantee’s estate or designated
beneficiary.
	 
	10.	 	Taxes. Grantee understands that Grantee will recognize income for federal and, if
applicable, state income tax purposes in an amount equal to the amount by which the fair
market value of the Shares, as of the Grant Date or vesting date, as applicable, exceeds any
consideration paid by Grantee for such Shares. Grantee shall be liable for any and all taxes,
including withholding taxes, arising out of this grant or the vesting of Shares hereunder. By
accepting the Shares, Grantee covenants to report such income in accordance with applicable
federal and state laws. To the extent that the receipt of the Shares or the end of the
Restriction Period results in income to Grantee and withholding obligations of the Company,
including federal or state withholding obligations, Grantee agrees that the Company shall
retain and instruct a registered broker(s) to sell such number of Shares necessary to satisfy
the Company’s withholding obligations, after deduction of the broker’s commission, and the
broker shall remit to the Company the cash necessary in order for the Company to satisfy its
withholding obligations. Grantee covenants to execute any such documents as are requested by
the broker of the Company in order to effectuate the sale of the Shares and payment of the tax
obligations to the Company. The Grantee represents to the Company that, as of the date
hereof, he or she is not aware of any material nonpublic information about the Company or the
Shares. The Grantee and the Company have structured this Agreement to constitute a “binding
contract” relating to the sale of Shares pursuant to this Section, consistent with the
affirmative defense to liability under Section 10(b) of the Exchange Act under Rule 10b5-1(c)
promulgated under the Exchange Act.




 









 




Restricted Stock Grant Agreement

Page 5




	11.	 	Representations. By accepting the Shares, Grantee represents and warrants for Grantee and
Grantee’s transferees (whether by will or the laws of descent and distribution) that:






(a) The sale and marketing of the Company’s products by Grantee are Grantee’s primary
trade or business.




(b) During the most recently ended calendar year Grantee derived, and during the current
calendar year Grantee expects to derive, the majority of Grantee’s earned income from
the sales and marketing of the Company’s products.




	12.	 	Miscellaneous.






	 	12.1.	 	The Company shall not be required (i) to transfer on its books any shares of Stock of
the Company which have been sold or transferred in violation of any provisions set forth in
this Agreement, or (ii) to treat as owner of such shares or to accord the right to vote as
such owner or to pay dividends to any transferee to whom such shares shall have been so
transferred.
	 
	 	12.2.	 	The parties agree to execute such further instruments and to take such action as may
be reasonably necessary to carry out the intent of this Agreement.
	 
	 	12.3.	 	Any notice required or permitted hereunder shall be given in writing and shall be
deemed effectively given upon delivery to Grantee at the address of Grantee then on file
with the Company.
	 
	 	12.4.	 	Neither the Plan nor this Agreement nor any provisions under either shall be construed
so as to grant Grantee any right to remain associated with the Company or any of its
affiliates.
	 
	 	12.5.	 	This Agreement constitutes the entire agreement of the parties with respect to the
subject matter hereof.





	 	 	 	 	 	 	 
	AGREED AND ACCEPTED:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	GRANTEE:	 	WRIGHT MEDICAL GROUP, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 


	 	 	 	 

Jason P. Hood, Vice President,

General Counsel, and Secretary